Stem Pharm, Inc.
Stem Pharm is a company focused on redefining neurologic drug discovery through advanced in vitro models, including human neural organoids featuring microglia for neuroimmune drug discovery. They develop synthetic biomaterials, such as hydrogels and pre-coated cell culture plates, to improve cell culture outcomes and enable sophisticated disease modeling and drug screening. Their mission is to leverage biomaterials and stem cell technologies to create physiologically relevant models for neurodegenerative diseases, neuroinflammation, and other neurological conditions, ultimately advancing drug discovery and reducing reliance on animal testing.
Industries
Nr. of Employees
small (1-50)
Stem Pharm, Inc.
Products
Pre-coated synthetic-substrate 96-well imaging plates (pre-coated cell culture plates)
Ready-to-use imaging-grade multiwell plates pre-coated with a chemically-defined synthetic substrate designed to improve cell adhesion, accelerate maturation, and enhance assay performance; shelf-stable and ready for immediate plating.
Ready-to-dispense chemically-defined hydrogel formulations
Frozen and optically clear PEG-based hydrogel formulations supplied for organoid generation, spheroid encapsulation, and automated dispensing; two formulation classes optimized for adhesion-driven assays and for encapsulation/expansion of 3D structures.
Pre-coated synthetic-substrate 96-well imaging plates (pre-coated cell culture plates)
Ready-to-use imaging-grade multiwell plates pre-coated with a chemically-defined synthetic substrate designed to improve cell adhesion, accelerate maturation, and enhance assay performance; shelf-stable and ready for immediate plating.
Ready-to-dispense chemically-defined hydrogel formulations
Frozen and optically clear PEG-based hydrogel formulations supplied for organoid generation, spheroid encapsulation, and automated dispensing; two formulation classes optimized for adhesion-driven assays and for encapsulation/expansion of 3D structures.
Services
Neurological disease modeling and organoid generation
Custom generation of human iPSC-derived neural organoids and disease-focused models (neuroinflammation, neurodegeneration, glioblastoma, epilepsy, developmental disorders) including incorporation of microglia and other cell types.
Assay development, phenotypic screening and neurotoxicity assessment
Development and execution of phenotypic screens, high-content imaging assays, immunoassays, vascular and neurotoxicity assays, and related data analysis workflows.
Custom biomaterials design and DOE optimization
Design, optimization (DOE), and testing of synthetic hydrogels and surface coatings tailored to specific cell types and assay requirements, with performance testing on adhesion, differentiation, and maturation.
Bioinformatics and multi-omic data analysis
Computational analysis and interpretation of transcriptomic and imaging datasets to support target identification, pathway analysis, and hit selection.
Pilot project engagements for model evaluation
Short-term pilot studies to evaluate organoid model suitability, assay performance, and to generate case-study data for decision-making in early discovery programs.
Neurological disease modeling and organoid generation
Custom generation of human iPSC-derived neural organoids and disease-focused models (neuroinflammation, neurodegeneration, glioblastoma, epilepsy, developmental disorders) including incorporation of microglia and other cell types.
Assay development, phenotypic screening and neurotoxicity assessment
Development and execution of phenotypic screens, high-content imaging assays, immunoassays, vascular and neurotoxicity assays, and related data analysis workflows.
Custom biomaterials design and DOE optimization
Design, optimization (DOE), and testing of synthetic hydrogels and surface coatings tailored to specific cell types and assay requirements, with performance testing on adhesion, differentiation, and maturation.
Bioinformatics and multi-omic data analysis
Computational analysis and interpretation of transcriptomic and imaging datasets to support target identification, pathway analysis, and hit selection.
Pilot project engagements for model evaluation
Short-term pilot studies to evaluate organoid model suitability, assay performance, and to generate case-study data for decision-making in early discovery programs.
Expertise Areas
- Human iPSC-derived neural tissue modeling
- Neuroinflammation and microglia biology
- Synthetic biomaterials for cell culture
- In vitro phenotypic drug discovery
Key Technologies
- Human iPSC-derived organoids
- PEG-based chemically defined hydrogels
- Pre-coated imaging-grade multiwell culture plates
- Bulk and single-cell RNA sequencing